Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer. Issue 7 (August 2017)

• Record Type: Journal Article
• Authors: Stahler, Arndt; Heinemann, Volker; Neumann, Jens; Crispin, Alexander; Schalhorn, Andreas; Stintzing, Sebastian; Giessen-Jung, Clemens; Fischer von Weikersthal, Ludwig; Vehling-Kaiser, Ursula; Stauch, Martina; Quietzsch, Detlef; Holch, Julian W.; Kruger, Stephan; Haas, Michael; Michl, Marlies; von Einem, Jobst; Kirchner, Thomas; Jung, Andreas; Modest, Dominik P.
• Is Part Of: Anti-cancer drugs. Volume 28:Issue 7(2017)
• Publication Date: 2017-08
• Subjects: biomarker -- HER2/neu -- HER3 -- metastatic colorectal cancer -- neuregulin 1; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000510
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Our aim was to explore the impact of the HER2/neu, HER3 receptor as well as their ligands' neuregulin ( NRG1) expression on the outcome of patients with metastatic colorectal cancer (mCRC). NRG1, HER2/neu and HER3 expression was evaluated in 208 patients with mCRC receiving 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as the first-line treatment. Biomarker expression was correlated with the outcome of patients. NRG1 (low: 192 vs. high: 16), HER2/neu (low: 201 vs. high: 7) and HER3 (low: 69 vs. high: 139) expressions were assessed in 208 patients. High versus low NRG1 expression significantly affected progression-free survival (PFS) [4.7 vs. 8.2 months, hazard ratio (HR): 2.45; 95% confidence interval (CI): 1.45–4.13; P =0.001], but not overall survival (OS) (15.5 vs. 20.7 months, HR: 1.33; 95% CI: 0.76–2.35; P =0.32). High versus low HER3 expression (PFS: 7.1 vs. 8.8 months, HR: 1.11; 95% CI: 0.82–1.50; P =0.50; OS: 19.8 vs. 21.1 months, HR: 0.95; 95% CI: 0.70–1.30; P =0.75) and high compared with low HER2/neu expression (PFS: 7.7 vs. 8.0 months, HR: 1.07; 95% CI: 0.71–1.60; P =0.75; OS: 16.6 vs. 21.1 months, HR: 1.13; 95% CI: 0.75–1.71; P =0.57) did not influence outcome. High NRG1 expression was associated with inferior PFS in the FIRE-1 trial. We did not detect a prognostic impact of HER2/neu and HER3 overexpression in mCRC. The frequency of overexpression was comparable with other studies.